2026 年 3 月 6 日 总量联合行业 "开局之年"行稳致远，孕育资本市场新机遇 ——2026 年政府工作报告精神学习之联合报告 要点 2026 年 3 月 5 日，十四届全国人大四次会议开幕，国务院总理李强向大会作政 府工作报告。我们的学习体会如下： 今年政府工作报告体现出务实进取、谋划长远的政策取向。总量层面，下调经济 目标增速，但强调努力争取最好结果；价格层面，明确指出"推动价格总水平由 负转正"，深入整治"内卷式"竞争及扩大内需仍是主要抓手。工作思路上：1） 保持积极的财政扩张政策，加大对投资和消费的支持力度；2）紧抓战略窗口期， 寻找经济的新增长点；3）深化重点领域改革，增强内生动能。 具体从各行业看： 银行：银行体系全年扩表仍将保持一定强度，叠加息差收窄压力同比缓释，将对 利息收入形成有力支撑，手续费也有望延续回暖态势，预估上市银行 2026 年营 收增速小幅上修至 2%附近。 房地产：2026 开年《求是》刊文，明确改善和稳定房地产预期，随着供给侧逐 步出清，部分信用优势明显的龙头央国企地产将持续受益于竞争结构优化，建议 关注招商蛇口、中国金茂、上海临港、绿城服务等。 石化&基化：（1）能源 ...

证券之星消息，截至2026年2月27日收盘，可孚医疗(301087)报收于57.75元，上涨3.11%，换手率 1.63%，成交量3.16万手，成交额1.81亿元。 2月27日的资金流向数据方面，主力资金净流入2289.02万元，占总成交额12.68%，游资资金净流出 1232.51万元，占总成交额6.82%，散户资金净流出1056.52万元，占总成交额5.85%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近5日资金流向一览见下表： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元， ...

证券之星消息，截至2026年2月26日收盘，可孚医疗(301087)报收于56.01元，上涨0.81%，换手率 0.87%，成交量1.7万手，成交额9447.76万元。 2月26日的资金流向数据方面，主力资金净流入501.59万元，占总成交额5.31%，游资资金净流入377.1 万元，占总成交额3.99%，散户资金净流出878.68万元，占总成交额9.3%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为53.84。 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗 ...

可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为53.84。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 证券之星消息，截 ...

证券之星消息，截至2026年2月13日收盘，可孚医疗(301087)报收于56.25元，上涨0.54%，换手率 1.15%，成交量2.23万手，成交额1.26亿元。 2月13日的资金流向数据方面，主力资金净流入1115.3万元，占总成交额8.88%，游资资金净流入537.28 万元，占总成交额4.28%，散户资金净流出1652.59万元，占总成交额13.16%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有6家机构给出评级，买入评级5家，增持 ...

Core Viewpoint - The stock of Kefu Medical (301087) has shown a positive performance with a closing price of 55.2 yuan, reflecting a 1.28% increase as of February 10, 2026, with significant trading activity and a notable net inflow of funds [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders reached 260 million yuan, up 3.3% year-on-year, while the net profit after deducting non-recurring items was 222 million yuan, reflecting a 1.46% increase [2] - In Q3 2025 alone, the company achieved a quarterly revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2] - The quarterly net profit attributable to shareholders was approximately 92.83 million yuan, which is a 38.68% increase year-on-year, and the net profit after deducting non-recurring items was about 85.80 million yuan, up 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2] Market Activity - On February 10, 2026, the stock experienced a trading volume of 25,100 hands and a total transaction amount of 139 million yuan [1] - The net inflow of main funds was 10.61 million yuan, accounting for 7.65% of the total transaction amount, while retail investors saw a net outflow of 8.20 million yuan, representing 5.91% of the total [1]

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Kefu Medical (301087) as of February 9, 2026, with a closing price of 54.5 yuan, reflecting a slight increase of 0.06% [1] - Kefu Medical's main business includes the research, production, sales, and service of home medical devices [1] - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [1] Group 2 - In the third quarter of 2025, Kefu Medical achieved a single-quarter main revenue of 902 million yuan, representing a significant year-on-year increase of 30.72%, and a net profit attributable to shareholders of approximately 92.83 million yuan, up 38.68% year-on-year [1] - The company’s financial metrics include a debt ratio of 27.37%, investment income of 18.18 million yuan, financial expenses of -3.77 million yuan, and a gross profit margin of 53.35% [1] - Over the past 90 days, five institutions have provided ratings for the stock, with four buy ratings and one hold rating, and the average target price set at 54.92 yuan [2]

证券之星消息，截至2026年2月6日收盘，可孚医疗(301087)报收于54.47元，上涨0.15%，换手率 1.51%，成交量2.94万手，成交额1.6亿元。 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为 54.92。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分 ...

Group 1 - The stock price of Kefu Medical (301087) closed at 54.39 yuan on February 5, 2026, with an increase of 1.49% and a turnover rate of 2.32% [1] - The trading volume was 45,100 hands, with a total transaction amount of 244 million yuan [1] - The net inflow of main funds was 1.1153 million yuan, accounting for 0.46% of the total transaction amount, while retail investors had a net outflow of 28.4653 million yuan, accounting for 11.64% [1] Group 2 - In the financing and securities lending data, the financing buy amounted to 21.9706 million yuan, with a net financing purchase of 7.5677 million yuan [2] - The stock had a financing and securities lending balance of 160 million yuan [2] - The company reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [3] Group 3 - In Q3 2025, the company achieved a single-quarter main revenue of 900.2 million yuan, a year-on-year increase of 30.72%, and a net profit of approximately 92.8298 million yuan, up 38.68% year-on-year [3] - The company’s gross profit margin was 53.35%, with a debt ratio of 27.37% [3] - Over the past 90 days, five institutions provided ratings for the stock, with four buy ratings and one hold rating, and the average target price was 54.92 yuan [3]

Group 1 - The core viewpoint of the article highlights the performance and financial metrics of Kefu Medical (301087) as of February 4, 2026, showing a stock price increase and specific capital flow data [1] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.63% [2] - The net profit attributable to the parent company for the same period was 260 million yuan, up 3.3% year-on-year, with a net profit margin of 53.35% [2] Group 2 - In Q3 2025, Kefu Medical achieved a single-quarter revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72% [2] - The company’s net profit for Q3 2025 was approximately 92.83 million yuan, marking a year-on-year increase of 38.68% [2] - The company has a debt ratio of 27.37% and reported investment income of 18.18 million yuan, with financial expenses recorded at -3.77 million yuan [2] Group 3 - The stock has received ratings from five institutions in the last 90 days, with four buy ratings and one hold rating, and the average target price set at 5.492 billion yuan [2] - As of February 4, 2026, the stock's trading volume was 23,000 hands, with a total transaction amount of 121 million yuan [1] - The capital flow data indicates a net inflow of 6.78 million yuan from main funds, accounting for 5.59% of the total transaction amount [1]